Celltrion, CJ Bioscience strengthen European presence at ECCO'25
Celltrion and CJ Bioscience are set to showcase their global competitiveness through research findings at the 2025 European Crohn's and Colitis Organization congress, one of the world's most prestigious inflammatory bowel disease research gatherings, which kicked off Thursday in Berlin.
As Europe's largest IBD conference, ECCO draws over 8,000 medical professionals annually from around the world, including North America and Asia. The four-day event serves as a key platform for discussions on cutting-edge clinical research and emerging treatment approaches. Celebrating its 20th anniversary, this year's conference is themed 'Sustainability in IBD and Beyond.'
As the only Korean company participating as an official sponsor, Celltrion is aiming to make a strong impact with a dedicated booth showcasing scientific programs.
The company is set to present research findings on the treatment outcomes of moderate to severe ulcerative colitis patients using Remsima SC. Additionally, Celltrion will unveil three poster presentations, covering clinical recovery time after dose escalation in patients with loss of response, the efficacy of maintenance therapy based on disease location in Crohn's disease patients, and the impact of immunogenicity in two-year clinical data from Crohn's disease patients.
'The newly presented research data is expected to further strengthen the preference for Remsima SC,' a Celltrion official said. 'It will not only reinforce our position in Europe but also enhance trust in our products in key regions such as the US, Asia and Latin America, where we are preparing for prescription expansion and new product launches.'
According to market research firm IQVIA, Remsima SC has captured 25 percent of the market share across five major European countries -- Germany, Spain, the UK, Italy and France, as of the third quarter of 2024. When combined with the intravenous formulation of Remsima, the overall market share across these EU nations reaches 79 percent.
Meanwhile, marking its first-ever participation at ECCO, CJ Bioscience is unveiling its latest research findings on CJRB-201, a promising microbiome-based drug candidate developed through Ez-Mx, an AI-powered drug discovery platform. The company will present new data on the drug's anti-inflammatory effects and mechanism of action, backed by immune analysis and animal studies.
"While antibody-based therapies are often challenging to administer and lack sustained safety, CJRB-201 is designed to offer superior safety and enhanced usability for prolonged treatment," a CJ Bioscience official said, adding that the company is preparing to initiate clinical development next year.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
a day ago
- Korea Herald
Trump says Iran deal would not allow 'any' uranium enrichment
WASHINGTON (AFP) — US President Donald Trump on Monday ruled out allowing Iran to enrich uranium under any nuclear deal between the foes — as Tehran defended what it said was its "peaceful" pursuit of fuel for power generation. Uranium enrichment has remained a key point of contention in five rounds of talks since April to ink a new accord to replace the deal with major powers that Trump abandoned during his first term in 2018. "Under our potential Agreement — WE WILL NOT ALLOW ANY ENRICHMENT OF URANIUM!" Trump said on his Truth Social network after the Axios news outlet said Washington's offer would let Tehran enrich some of the nuclear fuel. Republican Trump also blamed predecessor Joe Biden for the impasse, saying the Democrat "should have stopped Iran a long time ago from 'enriching.'" Axios said the latest proposal that Washington had sent Tehran on Saturday would allow limited low-level uranium enrichment on Iranian soil, for an amount of time that has yet to be determined. Iran has insisted that Iran has "nothing to hide" on its nuclear program. Speaking in Cairo, where he met the UN nuclear watchdog's chief Rafael Grossi, Iran's Foreign Minister Abbas Araghchi said, "If the goal is to deprive Iran of its peaceful activities, then certainly no agreement will be reached." The remarks came after Grossi of the International Atomic Energy Agency on Monday called for more transparency from Iran following a leaked report that showed Tehran had stepped up uranium enrichment. The IAEA report showed that Iran has ramped up production of uranium enriched up to 60 percent — close to the roughly 90 percent level needed for atomic weapons. "There is a need for more transparency — this is very, very clear — in Iran, and nothing will bring us to this confidence (besides) full explanations of a number of activities," Grossi said ahead of meeting Araghchi. Grossi added that some of the report's findings "may be uncomfortable for some, and we are ... used to being criticized." Iran has rejected the report, warning it would retaliate if European powers that have threatened to reimpose nuclear sanctions "exploit" it. "Some countries are trying to abuse this agency to pave the way for escalation with Iran. I hope that this agency does not fall into this trap," Araghchi said of the IAEA. Iran meanwhile pushed for the United States to drop sanctions that have crippled its economy as a condition for a nuclear agreement with Trump's administration. Araghchi said Saturday that he had received "elements" of the US proposal for a nuclear deal following the five rounds of talks, mediated by Oman. Both Araghchi and Grossi met Egyptian President Abdel Fattah el-Sissi, who praised the US-Iran talks and called for "de-escalation in order to prevent a slide into a full-fledged regional war." On Monday, Iranian Foreign Ministry spokesperson Esmaeil Baqaei told a news conference: "We want to guarantee that the sanctions are effectively lifted." "So far, the American side has not wanted to clarify this issue," he said. The US envoy in the nuclear talks said last month that Trump's administration would oppose any Iranian enrichment. "An enrichment program can never exist in the state of Iran ever again. That's our red line. No enrichment," Steve Witkoff told Breitbart News. Following a phone call with Witkoff the day before about the ongoing nuclear talks, Egyptian Foreign Minister Badr Abdelatty urged a peaceful solution and a nuclear-weapon-free Middle East, saying in Monday's press conference that "the region is already experiencing enough problems and crises." He warned that military confrontation would create "a state of chaos from which no one will be spared." Iran has vowed to keep enriching uranium "with or without a deal" on its nuclear program. The United States has sent Iran a proposal for a nuclear deal that the White House called "acceptable" and in Tehran's "best interest" to accept, US media reported Saturday. The New York Times, citing officials familiar with the diplomatic exchanges, said the proposal calls on Iran to stop all enrichment and suggests creating a regional grouping to produce nuclear power.
Korea Herald
a day ago
- Korea Herald
FinPrime Secures Dual Wins at World Business Outlook Awards 2025
PORT LOUIS, Mauritius, June 2, 2025 /PRNewswire/ -- FinPrime, a leading global prime brokerage, has been honoured with two prestigious titles at the World Business Outlook Awards 2025: Best Liquidity Provider of the Year, Australia 2025, and Best Liquidity Provider in Emerging Markets, Europe 2025. These recognitions underscore FinPrime's commitment to delivering superior liquidity solutions and its growing influence in global financial markets. Recognising Industry Excellence The World Business Outlook Awards celebrate organisations that exemplify exceptional leadership, innovation, and global impact across various industries. With a rigorous evaluation process led by a distinguished jury, the awards highlight firms that set new benchmarks in their respective fields. FinPrime's dual wins reinforce its standing as a trusted liquidity provider, dedicated to serving institutional clients with cutting-edge solutions and seamless execution. Best Liquidity Provider of the Year, Australia 2025 FinPrime's recognition as Best Liquidity Provider of the Year in Australia reflects its strategic expansion and the strength of its institutional offerings in the region. Through advanced trading technology, deep liquidity access, and robust risk management tools, FinPrime has established itself as a key player in Australia's financial ecosystem. Best Liquidity Provider in Emerging Markets, Europe 2025 FinPrime's recognition as Best Liquidity Provider in Emerging Markets, Europe highlights its ability to navigate the complexities of evolving financial landscapes while delivering unparalleled service. By leveraging deep market expertise and proprietary technology, FinPrime has successfully positioned itself as a go-to liquidity provider for institutional clients across emerging European markets. The CEO of FinPrime shared: "We are incredibly honoured to receive these awards from World Business Outlook. They affirm our dedication to providing best-in-class liquidity solutions and reinforce our mission to empower institutional clients with the tools and technology needed to thrive in today's dynamic financial markets. As we continue our global expansion, we remain committed to delivering innovation, reliability, and excellence." Looking Ahead Winning at the World Business Outlook Awards 2025 marks a significant milestone for FinPrime, solidifying its position as a leading liquidity provider on the global stage. As the firm continues to grow, its core mission remains unchanged—to empower institutional clients with superior liquidity solutions, cutting-edge technology, and world-class service. . FinPrime is a global prime brokerage firm that provides institutional clients with access to deep liquidity, advanced trading platforms, and sophisticated risk management solutions. Regulated by the Mauritius Financial Services Commission (FSC), FinPrime is dedicated to driving innovation and delivering seamless financial services across global markets.
Korea Herald
2 days ago
- Korea Herald
Solus to supply key EV battery material to CATL's European plants
Korean battery materials producer Solus Advanced Materials announced Monday that it has secured a contract to supply electrolytic copper foil to Chinese electric vehicle battery juggernaut CATL. Under the agreement, Solus will deliver the key battery component from its Hungarian plant to support CATL's rapidly expanding operations across Europe. While Solus did not disclose the duration or volume of the deal, it confirmed that deliveries will begin in 2026. This marks the first time a Korean foil manufacturer has been selected to supply CATL's European operations. Solus attributed its successful bid to its position as the only Korean electrolytic foil producer currently operating in Europe as well as its technical expertise in foil manufacturing and rapid delivery capabilities. 'This new collaboration with CATL, a powerhouse in the global battery market, confirms Solus Advanced Materials' global competitiveness,' said Solus CEO Kwak Keun-man. 'Through this partnership, we will accelerate innovation in elecfoil technology and fully support CATL in building a localized supply chain in Europe, ultimately enhancing customer satisfaction.' CATL, the world's largest battery maker, currently runs a 14 gigawatt-hour plant in Erfurt, Germany, and is set to open a 100 GWh facility in Hungary later this year. A third plant, co-developed with European automaker Stellantis, is planned for Spain with an expected opening in 2026 — part of CATL's broader strategy to solidify its foothold in the European market amid growing policy headwinds in the US. Solus added that both companies are also exploring joint development of next-generation products. The market responded positively to the announcement. Shares of Solus surged at the opening of Korea's main bourse, Kospi, reaching as high as 10,990 won ($14.51), a 28 percent increase from the previous day's close. As of 12:53 p.m., the stock was trading at 9,790 won, up 14.1 percent from the previous day.
